January 19^th - 20^th, 2006
Brussels, Belgium

The desire to bring new drugs to market faster is a key driver of pharmaceutical companies. Being able to identify drug candidates faster with fewer missed hits has streamlined the screening process, but having insufficient knowledge of potential human toxicity early on can turn a successful drug into a devastating loss.

Promega and Mondial Research have joined as strategic partners to bring together scientific experts to present and discuss recent advances towards accurately predicting human toxicities and screening earlier in the drug discovery process. This event will also cover topics on toxicogenomics, in-silico tools, ADME/Tox and pharmacokinetics. Our goal is to provide a platform for forging a better understanding of the issues at hand in order that regulatory agencies may develop better policies and to assist the pharmaceutical industry in delivering safer drugs to market.

Agenda